The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...
Guests: Sonali Kolhatkar is an award-winning multimedia journalist and Senior Editor at YES! Media. She is also the host of Rising Up with Sonali, a nationally syndicated TV and radio program that ...
The Post welcomes letters up to 250 words on topics of general interest. Letters must include full name, home address, day and evening phone numbers, and may be edited for length, grammar and ...
FOOD FOR THOUGHT I listened to Olivia Chow’s passionate speech on how the poor Uber drivers can’t survive on less than minimum wage and her pleas to rectify the problem. If only she could ...